Last reviewed · How we verify
MMR vaccine (Priorix)
Priorix is a live attenuated vaccine that stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses.
Priorix is a live attenuated vaccine that stimulates the immune system to produce antibodies and cellular immunity against measles, mumps, and rubella viruses. Used for Prevention of measles, Prevention of mumps, Prevention of rubella.
At a glance
| Generic name | MMR vaccine (Priorix) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains weakened (attenuated) strains of measles, mumps, and rubella viruses that replicate in the body without causing disease. This triggers both humoral (antibody) and cell-mediated immune responses, providing long-term protection against infection with wild-type viruses. The immune memory generated prevents or significantly reduces severity of infection upon exposure to these pathogens.
Approved indications
- Prevention of measles
- Prevention of mumps
- Prevention of rubella
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Rash
- Parotitis (mumps-like symptoms)
- Arthralgia/arthritis
Key clinical trials
- Live Vaccines and Innate Immune Training in COPD. (PHASE4)
- Is a Third Dose of MMRV Vaccine Beneficial for the Adult Population in Alberta?
- A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population (PHASE3)
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age (PHASE3)
- Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MMR vaccine (Priorix) CI brief — competitive landscape report
- MMR vaccine (Priorix) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI